ライフサイエンスコーパス: refractory ascites

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 urvival times of patients with cirrhosis and refractory ascites.

2 ment during follow-up evaluation, mainly for refractory ascites.

3 tic portosystemic shunt in the management of refractory ascites.

4 repeated large volume paracentesis (LVP) for refractory ascites.

5 may improve quality of life in patients with refractory ascites.

6 from the early ascitic stage to the stage of refractory ascites.

7 urvival times of patients with cirrhosis and refractory ascites.

8 n of variceal rebleeding or for treatment of refractory ascites.

9 n of variceal rebleeding or for treatment of refractory ascites.

10 variceal rebleeding and 58 for treatment of refractory ascites.

11 ssure and have been used in the treatment of refractory ascites.

12 .024) as predictors for ELF in patients with refractory ascites.

13 ild-Pugh class C cirrhosis, hyponatremia, or refractory ascites.

14 The most frequent indication for TIPS was refractory ascites (50 of 54; 93%).

15 e mortality in the subgroup of patients with refractory ascites (588 patients, adjusted hazard ratio

16 he model for end-stage liver disease (MELD), refractory ascites, a known predictor of mortality in ci

17 he North American Study for the Treatment of Refractory Ascites, a multicenter trial of 109 patients

18 ntagonist) was investigated for treatment of refractory ascites and appeared to be effective, but thi

19 sequelae of end-stage liver disease such as refractory ascites and esophageal varices for patients a

20 F occurred in 16 of 95 (16.8%) patients with refractory ascites and in four of 121 (3.3%) patients wi

21 PS placement for variceal hemorrhage, 49 for refractory ascites, and 24 for hepatic hydrothorax (tota

22 ratios were 4.6 and 4.3 in the patient with refractory ascites at the two post-TIPS time points, res

23 seven patients with portal hypertension and refractory ascites before and 2 and 12 weeks after TIPS

24 of 12 or less who undergo TIPS placement for refractory ascites (especially in patients with MELD of

25 Large or refractory ascites frequently necessitates paracentesis.

26 nderwent TIPS creation for the management of refractory ascites had a significantly lower survival ra

27 Refractory ascites is managed by repeated large volume p

28 -vis total paracentesis in the management of refractory ascites is unclear.

29 ere recurrent variceal bleeding (n = 25) and refractory ascites (n = 16).

30 of recurrent variceal hemorrhage (n = 40) or refractory ascites (n = 20) were studied.

31 temic shunt is indicated when control of the refractory ascites or hepatic hydrothorax is required.

32 ic shunt (TIPS) is used in the management of refractory ascites (RA) and variceal bleeds.

33 utive series of patients with cirrhosis with refractory ascites (RA).

34 In conclusion, patients with refractory ascites randomized to TIPS or repeated LVP ha

35 In a controversial study, patients with refractory ascites taking propranolol were found to have

36 Patients with refractory ascites taking propranolol were found to have

37 ices, gastroesophageal variceal bleeding and refractory ascites than sub-acute group (P < 0.001).

38 In 50 patients with refractory ascites, TIPS creation was performed.

39 ial was performed in which 109 subjects with refractory ascites were randomized to either medical the

40 Treating medically refractory ascites with TIPS risks early shunt-related m

41 nts for whom an indication for TIPS had been refractory ascites, with a history of OHE or of renal fa

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。